5 Best Biotech Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
In this article, we discuss the 5 best biotech stocks to buy according to Mark Lampert.
Protagonist Therapeutics Inc (PTGX)
Get Email Alerts Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 4,387,300 | $77,743 | +280% | 0.34% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,901,759 | $69,139 | +4% | 2.69% |
| 3. | Farallon Capital Thomas Steyer | 2,392,000 | $42,386 | +3% | 0.21% |
| 4. | EcoR1 Capital Oleg Nodelman | 1,443,800 | $25,584 | 0.89% | |
| 5. | Deerfield Management James E. Flynn | 1,394,000 | $24,702 | +3% | 0.48% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.70 | 12,000 | Director | 15,310 | 2020-03-12 | Filing | |
| $5.70 | 8,000 | Director | 8,000 | 2019-12-03 | Filing | |
| $5.13 | 30,000 | Officer | 49,500 | 2019-12-03 | Filing | |
| $5.09 | 562 | Officer | 1,175 | 2019-12-03 | Filing | |
| $5.10 | 613 | Officer | 613 | 2019-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.56 | 14,779 | Officer | 58,254 | 2021-08-17 | Filing | |
| $25.09 | 3,700 | Director | 0 | 2021-02-11 | Filing | |
| $26.04 | 400 | Director | 0 | 2021-02-10 | Filing | |
| $25.42 | 4,300 | Director | 400 | 2021-02-10 | Filing | |
| $24.60 | 24,846 | Officer, Director | 426,144 | 2021-01-19 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 27,598 | $489,037 | 0% | |
| 2. | 8,007 | $141,884 | 0% | |
| 3. | 6,492,638 | $115,049 | 0% | |
| 4. | 3,199,496 | $56,695 | 0% | |
| 5. | 2,449,183 | $43,400 | 3.8% |
News See All
5 Pharma Stocks to Buy According to Mark Lampert’s Biotechnology Value Fund
Below is the list of 5 pharma stocks to buy according to Mark Lampert’s Biotechnology Value Fund.
Hedge Funds Are Crazy About Protagonist Therapeutics, Inc. (PTGX)
At Insider Monkey, we pore over the filings of nearly 873 top investment firms every quarter, a process we have now completed for the latest reporting period.
Protagonist Therapeutics, Inc. (PTGX) Fell Out Of Favor With Hedge Funds
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Is PTGX Stock A Buy or Sell?
In this article you are going to find out whether hedge funds think Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a good investment right now.
Is PTGX A Good Stock To Buy Now?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Protagonist Therapeutics, Inc. (PTGX): Are Hedge Funds Right About This Stock?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Here is What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November.
Here’s What Hedge Funds Think About Protagonist Therapeutics, Inc. (PTGX)
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the first quarter, which unveil their equity positions as of March 31...
Market Movers Today: Biohaven Pharmaceutical Holding Co Ltd (BHVN), Facebook, Inc. (FB), Longfin Corp (LFIN), Verona Pharma PLC – ADR (VRNA), and More
Biohaven Pharmaceutical Holding Co. Ltd.
Billionaire Hedge Funds
